Domestic three-generation insulin breaks foreign monopoly 20%-30% cheaper than similar imported products

Ji Linon, honorary chairman of the Diabetes Credit Association of the Chinese Medical Association and director of the Endocrinology Department of Peking University People's Hospital, said in an interview recently that clinical trials show that the insulin glycerin developed by China's Glyceride Pharmaceuticals has biological equivalents compared with imported insulin insulin, which has successfully broken the long-term monopoly of imported products and become the first biosynthic product to be listed in the field of insulin in three generations. Cheap domestic insulin will "reduce the burden" on already overburdened health insurance.
" according to the introduction, the number of diabetes patients in China has reached 110 million people, becoming the world's largest number of diabetes countries. The cost of diabetes treatment in China amounts to 173.4 billion yuan per year, and the direct medical expenses caused by diabetes already account for 13% of the total domestic medical expenses. In recent years, the development of biologics has brought new breakthroughs to the medical industry, but has also significantly increased medical expenses. Insulin, for example, rose 197 percent from 2002 to 2013. Rising drug prices have put enormous pressure on health-care systems around the world, and even western developed countries cannot afford to let health-care costs rise. Therefore, the United States, the European Union has introduced policies to encourage the development of biosics. In order to meet the growing demand for health care from a large population, and to control the limited health care budget more strictly, biosoables provide an opportunity to help improve the level of health care while effectively controlling medical costs.
biosypolysts need to be tested in more clinical human trials than chemicals. "The development of biosics requires higher standards to ensure quality, " says Mr Guillalifer. Ensuring consistency with primary drugs is an important basis for the development of biosynthics, and the significance of clinical trials of biosynthics lies in reflecting their consistency with the original drug. Wang Xuzhou, deputy general manager of Ganli Pharmaceuticals, stressed that third-party clinical trial institutions in the United States have conducted equivalent research and analysis of domestic third-generation insulin and insulin glycerine in the European and American markets, and the results show that the physical and chemical properties, three-dimensional structure and biological activity of Changxiuyu are not inferior to insulin glycelin in the European and American markets, while the price is about 20%-30% cheaper than similar imported products.
Since 2005, when global third-generation insulin sales surpassed second-generation insulin for the first time, recombinant insulin companies represented by insulin glycelin have become the drug of choice for the treatment of type 1 diabetes, accounting for more than 80% of the global insulin market share in terms of sales. Although China is the world's largest diabetes country, but the insulin market, especially insulin glycelin as the representative of the three generations of insulin market is mainly monopolized by imported products. Experts pointed out that with the domestic three generations of insulin into the market, the price of diabetes treatment drugs will gradually decline, which will not only greatly reduce the financial burden of patients, but also means that China's financial relief of hundreds of millions of yuan of economic burden. (China Economic Network)